文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

4F2hc/LAT1复合物可将左旋多巴转运穿过血脑屏障。

The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier.

作者信息

Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S

机构信息

Department of Neurology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, 606-8507, Kyoto, Japan.

出版信息

Brain Res. 2000 Oct 6;879(1-2):115-21. doi: 10.1016/s0006-8993(00)02758-x.


DOI:10.1016/s0006-8993(00)02758-x
PMID:11011012
Abstract

L-DOPA is transported across the blood-brain barrier (BBB) by an amino acid transporter, system L. Recently, it has been demonstrated that system L consists of two subunits, 4F2hc and either LAT1 or LAT2. 4F2hc/LAT1 and 4F2hc/LAT2 show different transport characteristics, while their distribution in the brain has not been determined. To clarify whether 4F2hc/LAT1 participates in L-DOPA transport across the BBB, we first examined the expression of 4F2hc/LAT1 in the mouse brain capillary endothelial cell line, MBEC4, as an in vitro BBB model. Northern hybridization and immunoblotting revealed that both 4F2hc and LAT1 are expressed and form a heterodimer in MBEC4 cells. To confirm whether 4F2hc/LAT1 acts as system L to transport L-DOPA, we characterized L-DOPA uptake into the cells. The uptake process was time-dependent, temperature-sensitive, and Na(+)-independent. Neutral amino acids with bulky side chains and a bicyclic amino acid, 2-aminobicyclo-[2, 2,1]-heptane-2-carboxylic acid (BCH), inhibited L-DOPA uptake into MBEC4 cells to a great extent, while an acidic amino acid, basic amino acids, and glycine had no effect. Other neutral amino acids, such as alanine, asparagine, glutamine, serine, and threonine inhibited L-DOPA uptake by 40-70% at most. These characteristics are more compatible with those of 4F2hc/LAT1, rather than those of 4F2hc/LAT2. Finally, immunohistochemistry with anti-LAT1 antibody demonstrated that LAT1 is predominantly expressed in the microvessels of the central nervous system. This is the first report showing that the 4F2hc/LAT1 complex participates in L-DOPA transport across the BBB.

摘要

左旋多巴通过氨基酸转运体L系统穿过血脑屏障(BBB)。最近,已证明L系统由两个亚基4F2hc和LAT1或LAT2组成。4F2hc/LAT1和4F2hc/LAT2表现出不同的转运特性,但其在脑中的分布尚未确定。为了阐明4F2hc/LAT1是否参与左旋多巴穿过血脑屏障的转运,我们首先在小鼠脑微血管内皮细胞系MBEC4(一种体外血脑屏障模型)中检测了4F2hc/LAT1的表达。Northern杂交和免疫印迹显示4F2hc和LAT1均有表达并在MBEC4细胞中形成异二聚体。为了证实4F2hc/LAT1是否作为L系统转运左旋多巴,我们对细胞摄取左旋多巴的特性进行了研究。摄取过程具有时间依赖性、温度敏感性且不依赖于Na(+)。带有大侧链的中性氨基酸和双环氨基酸2-氨基双环-[2, 2,1]-庚烷-2-羧酸(BCH)在很大程度上抑制了MBEC4细胞对左旋多巴的摄取,而酸性氨基酸、碱性氨基酸和甘氨酸则无影响。其他中性氨基酸,如丙氨酸、天冬酰胺、谷氨酰胺、丝氨酸和苏氨酸最多抑制40 - 70%的左旋多巴摄取。这些特性与4F2hc/LAT1的特性更相符,而非4F2hc/LAT2的特性。最后,用抗LAT1抗体进行免疫组织化学显示LAT1主要在中枢神经系统的微血管中表达。这是首次报道表明4F2hc/LAT1复合物参与左旋多巴穿过血脑屏障的转运。

相似文献

[1]
The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier.

Brain Res. 2000-10-6

[2]
LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine.

J Biol Chem. 1999-12-3

[3]
Characteristics of -citrulline transport through blood-brain barrier in the brain capillary endothelial cell line (TR-BBB cells).

J Biomed Sci. 2017-5-10

[4]
Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires different domains.

Biochem J. 2001-5-1

[5]
The heterodimeric amino acid transporter 4F2hc/LAT1 is associated in Xenopus oocytes with a non-selective cation channel that is regulated by the serine/threonine kinase sgk-1.

J Physiol. 2000-7-1

[6]
Expression of a system L neutral amino acid transporter at the blood-brain barrier.

Neuroreport. 2000-11-9

[7]
The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine.

Biochem J. 2000-8-1

[8]
Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier.

J Pharm Pharmacol. 2001-4

[9]
Cloning and functional characterization of a Na(+)-independent, broad-specific neutral amino acid transporter from mammalian intestine.

Biochim Biophys Acta. 2000-1-15

[10]
Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98).

J Biol Chem. 1998-9-11

引用本文的文献

[1]
Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.

BMC Cancer. 2025-8-15

[2]
Investigating white matter alterations in Parkinson's disease using multi-shell free-water DTI and NODDI: insights into neurodegeneration and levodopa effects.

Front Neurol. 2025-7-9

[3]
Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progression.

J Neural Transm (Vienna). 2025-4-11

[4]
Prodrug Approach as a Strategy to Enhance Drug Permeability.

Pharmaceuticals (Basel). 2025-2-21

[5]
Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system.

Nat Mater. 2025-2-17

[6]
Structural basis of anticancer drug recognition and amino acid transport by LAT1.

Nat Commun. 2025-2-14

[7]
Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function.

Adv Pharmacol. 2025

[8]
Amino acid transporter LAT1 is expressed on cancer cell-derived exosomes with potential as a diagnostic and prognostic biomarker.

Sci Rep. 2024-11-18

[9]
The Multifaceted Role of L-Type Amino Acid Transporter 1 at the Blood-Brain Barrier: Structural Implications and Therapeutic Potential.

Mol Neurobiol. 2025-3

[10]
Molecular Variability in Levodopa Absorption and Clinical Implications for the Management of Parkinson's Disease.

J Parkinsons Dis. 2024

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索